The COVID-19 vaccine development landscape

Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
No abstract available

Publication types

  • News

MeSH terms

  • Aged
  • Betacoronavirus* / immunology
  • COVID-19
  • COVID-19 Vaccines
  • Child
  • Clinical Trials, Phase I as Topic
  • Coronavirus Infections / genetics
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control*
  • Coronavirus Infections / virology
  • Drug Development*
  • Drug Industry
  • Female
  • Genetic Vectors
  • Humans
  • Internationality
  • Pandemics / prevention & control*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / prevention & control*
  • Pneumonia, Viral / virology
  • Pregnancy
  • SARS-CoV-2
  • Time Factors
  • Vaccines, Attenuated
  • Vaccines, Inactivated
  • Vaccines, Subunit
  • Vaccines, Synthetic
  • Viral Vaccines* / administration & dosage
  • Viral Vaccines* / chemistry
  • Viral Vaccines* / genetics
  • Viral Vaccines* / immunology

Substances

  • COVID-19 Vaccines
  • Vaccines, Attenuated
  • Vaccines, Inactivated
  • Vaccines, Subunit
  • Vaccines, Synthetic
  • Viral Vaccines